Reven Holdings laments hit to patent portfolio stemming from asset freeze
MLex Summary: Biotechnology and pharmaceutical company Reven Holdings, maker of the cardiovascular and anti-inflammatory drug Rejuveinix, is asking the US Court of Appeals for the Tenth Circuit to lift a freeze on...To view the full article, register now.
Already a subscriber? Click here to view full article